Narcolepsy Drugs Market Size & Share, by Disease Type (Extreme Sleepiness, Cataplexia); Therapeutics Type (Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Sodium Oxybate); End-user (Retail Pharmacies, Drug Stores, E-Commerce) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2767
  • Published Date: Apr 26, 2023
  • Report Format: PDF, PPT

Companies Dominating the Narcolepsy Drugs Landscape

top-features-companies
    • Ligand Pharmaceuticals Incorporated 
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Jazz Pharmaceuticals Inc.
    • Graymark Healthcare Inc.
    • BIOPROJET
    • Novartis AG
    • Teva Pharmaceuticals Industries Ltd.
    • Arena Pharmaceuticals Inc.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Ligand Pharmaceuticals Incorporated and GSK declared the Licence Agreement and the global growth of their relationship. The development is expected to be fueled by Icagen's particle discovery method and expertise in small-molecule therapeutics addressing membrane proteins.
  • Teva Pharmaceutical Industries Ltd. stated that they would spend USD 69 million to settle a Narcolepsy drug lawsuit in California. The reimbursement is expected to help the corporation in maintaining its monopoly in an industry where the rival corporation's Narcolepsy drugs will postpone their release by nearly six months.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2767
  • Published Date: Apr 26, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising prevalence of narcolepsy globally owing to the stressful lifestyle along with the surge in consumption of alcohol and tobacco is one of the major factors estimated to drive the growth of narcolepsy drugs market.

The market is anticipated to attain a moderate CAGR of 10% over the forecast period, i.e., 2023-2035.

Stringent government regulations regarding the agreement for narcolepsy drugs is identified as one of the factors expected to hamper the growth of the market over the forecast period.

The market in North America is estimated to garner the largest market share owing to the growing construction industry in the region, which creates further growth opportunities.

The major players in the market are Jazz Pharmaceuticals Inc., Graymark Healthcare Inc., BIOPROJET, Novartis AG, Teva Pharmaceuticals Industries Ltd., Arena Pharmaceuticals Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by disease type, therapeutics type, end users, and by region.

the extreme sleepiness segment is anticipated to hold largest market over the forecast period.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying